Defactinib clinical trials
Also written VS-6063 and PF-04554878.
Includes 3 studies of Defactinib hydrochloride.
Counted the way a researcher would: Defactinib with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses defactinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the defactinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 8 May 2025 · AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) · NDA 219616 (FDA, Drugs@FDA; as defactinib hydrochloride; in a combination)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2024 (6); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2013 | 5 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 6 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 21
Verastem, Inc. (11) · Memorial Sloan Kettering Cancer Center (3) · Washington University School of Medicine (3) · National Cancer Institute (NCI) (2) · Emory University (2) · M.D. Anderson Cancer Center (2) · Lei Zheng (1) · Girish Dhall, MD (1)
Often tested with
Tested in the same studies.
RO5126766 (15) · Adavosertib (1) · Afatinib (1) · Binimetinib (1) · Capivasertib (1) · Copanlisib (1) · Copanlisib hydrochloride (1) · Crizotinib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test defactinib.
- Dec 2026Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With GlioblastomaEarly Phase 1 · Emory University
- Mar 2027A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerPhase 2 · Memorial Sloan Kettering Cancer Center
- Apr 2027A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerPhase 2 · Memorial Sloan Kettering Cancer Center
- Aug 2027A Study of Avutometinib and Defactinib in People With Thyroid CancerPhase 2 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses defactinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 32
- Avutometinib and Defactinib in Diffuse Gastric CancerRecruitingPhase 2Ryan H. Moy, MD, PhDNCT06487221Written as Defactinib
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingPhase 3Verastem, Inc.NCT06072781Written as Defactinib
- Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath TumorNot yet recruitingPhase 2Girish Dhall, MDNCT07743554Written as avutometinib capsule + defactinib tablet
- A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06394804Written as Defactinib
- A Study of Avutometinib and Defactinib in People With Thyroid CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06007924Written as Defactinib
- Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT06369259Written as Defactinib
- Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT07318324Written as defactinib
- Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic AdenocarcinomaRecruitingPhase 2Washington University School of MedicineNCT07126158Written as Defactinib
- Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerRecruitingPhase 2Emory UniversityNCT06495125Written as Defactinib
- Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDSRecruitingPhase 1Clinical Hub for Interventional Research (CHOIR)NCT05636514Written as Defactinib
- 5G-RUBY: Avutometinib and Defactinib in Malignant Brain TumoursRecruitingPhase 1/2Institute of Cancer Research, United KingdomNCT06630260Written as Defactinib
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaRecruitingPhase 1/2University of UtahNCT06194929Written as Defactinib
- Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439331Written as Defactinib Hydrochloride
- A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05787561Written as Defactinib
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060Written as Defactinib
- Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas AdenocarcinomaActive, not recruitingPhase 2Washington University School of MedicineNCT04331041Written as Defactinib
- Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal AdenocarcinomaCompletedPhase 2Lei ZhengNCT03727880Written as Defactinib
- Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC PatientsActive, not recruitingPhase 1/2Verastem, Inc.NCT05074810Written as avutometinib and sotorasib and defactinib
- Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With GlioblastomaActive, not recruitingEarly Phase 1Emory UniversityNCT05798507Written as Defactinib
- Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal MelanomaTerminatedPhase 2Thomas Jefferson UniversityNCT04720417Written as Defactinib Hydrochloride
See all 32 studies that test defactinib →
Given beside what is tested · 3 — defactinib is usual care or a partner of the new treatment
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Defactinib
- ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAKTerminatedPhase 1/2Michael McHaleNCT03287271Written as VS-6063
- Phase I Trial of Defactinib and VS-6766.Active, not recruitingPhase 1Institute of Cancer Research, United KingdomNCT03875820Written as Defactinib
Codes
What other systems call defactinib · ClinicalTrials.gg INT006376
- MeSH (NLM) C584510defactinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 53O87HA2QUDEFACTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27077009defactinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C79809DefactinibOne source FDA
- DrugBank DB12282One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584510 | defactinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 53O87HA2QU | DEFACTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27077009 | defactinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C79809 | Defactinib | One source FDA |
| DrugBank | DB12282 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.